Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions’ Biomerk Tumorgraft™ platform.
B-Raf, a protein kinase, is a key part of a signaling pathway in the cell that leads to cell proliferation. A mutation in B-Raf is implicated in a wide-range of cancers, including melanoma, colorectal and ovarian cancer.
Under the terms of the agreement, Champions will use its Biomerk Tumorgraft™ to test the effectiveness of CEP-32496 in various cancer indications. “We are delighted to add Cephalon to Champions’ client list. The preclinical use of our highly-predictive Biomerk Tumorgraft™ platform will enable a greater understanding of the clinical potential of CEP-32496,” said Elizabeth Bruckheimer, Ph.D., Vice President of Scientific Operations, Champions Biotechnology, Inc.
Bruce Ruggeri, PhD, Senior Director, Oncology Research Drug Discovery at Cephalon stated, “We are excited to work with Champions. These results may be critical in appropriately designing clinical trials to further support the development of this compound.”
SOURCE Champions Biotechnology, Inc.